Dentists are often the first health professionals to see children with arthritis because the temporomandibular joints (TMJ) that enable chewing ...

The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

Patients with asthma demonstrate a heightened risk for developing osteoarthritis, a relationship that is particularly ...

Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

ST. LOUIS - With nearly 1.5 million people suffering from rheumatoid and juvenile arthritis in the United States, researchers ...

HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after ...